keyword
MENU ▼
Read by QxMD icon Read
search

Cancer death dying chemotherapy

keyword
https://www.readbyqxmd.com/read/29681240/pembrolizumab-combined-with-stereotactic-body-radiotherapy-in-a-patient-with-human-immunodeficiency-virus-and-advanced-non-small-cell-lung-cancer-a-case-report
#1
Dongqi Li, Chuanchun He, Yaoxiong Xia, Yaxi Du, Jing Zhang
BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with stereotactic body radiotherapy showed a slight toxicity and good benefits in recent clinical trials. However, patients infected with human immunodeficiency virus were excluded from most trials because it was assumed that their anti-tumor immunity was compromised compared with immunocompetent patients. CASE PRESENTATION: In June 2016, a 52-year-old Chinese man presented with human immunodeficiency virus and lung adenocarcinoma (T1bN3M1b)...
April 23, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29630020/disparities-in-adherence-to-national-comprehensive-cancer-network-treatment-guidelines-and-survival-for-stage-ib-iia-cervical-cancer-in-california
#2
Krista S Pfaendler, Jenny Chang, Argyrios Ziogas, Robert E Bristow, Kristine R Penner
OBJECTIVE: To evaluate the association of sociodemographic and hospital characteristics with adherence to National Comprehensive Cancer Network treatment guidelines for stage IB-IIA cervical cancer and to analyze the relationship between adherent care and survival. METHODS: This is a retrospective population-based cohort study of patients with stage IB-IIA invasive cervical cancer reported to the California Cancer Registry from January 1, 1995, through December 31, 2009...
April 6, 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29623487/atezolizumab-in-metastatic-urothelial-carcinoma-outside-clinical-trials-focus-on-efficacy-safety-and-response-to-subsequent-therapies
#3
Pedro C Barata, Dhrmesh Gopalakrishnan, Vadim S Koshkin, Prateek Mendiratta, Matt Karafa, Kimberly Allman, Allison Martin, Jennifer Beach, Pam Profusek, Allison Tyler, Laura Wood, Moshe Ornstein, Timothy Gilligan, Brian I Rini, Jorge A Garcia, Petros Grivas
BACKGROUND: Little is known about the outcomes, safety, and response to subsequent therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab outside clinical trials. OBJECTIVES: The objectives of the study include to report the clinical efficacy and safety of atezolizumab, and the response to future therapies in clinical practice outside clinical trials. PATIENT AND METHODS: This is a retrospective, single-center study including consecutive patients with confirmed mUC who received at least one dose of atezolizumab 1200 mg every 3 weeks between May 2016 and April 2017...
April 6, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29621999/histo-epidemiological-profile-of-breast-cancers-among-women-in-the-central-african-republic-about-174-cases
#4
Augustin Balekouzou, Ping Yin, Cavin Epi Bekolo, Christian Maucler Pamatika, Marceline Djeintote, Sylvain Wilfrid Nambei, Bertrand Ba-Mpoutou, Dieubeni Rawago Mandjiza, Chang Shu, Minghui Yin, Tingting Qing, Boniface Koffi
BACKGROUND: Breast cancer (BC) is the most common cancer in women worldwide and leading cause of cancer deaths indeveloping countries. There is very limited data on BC in the Central African Republic. The purpose of this study was to describe the epidemiological and histopathological characteristics of BC in Bangui. METHODS: This retrospective study reviewed cancer data registries and medical records from the Pathology Unit of the National Laboratory in Bangui and the General Surgery and Gyneacology service from 2003 to 2015...
April 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29588617/intensity-of-treatment-in-swiss-cancer-patients-at-the-end-of-life
#5
Caroline Bähler, Andri Signorell, Eva Blozik, Oliver Reich
Purpose: Current evidence on the care-delivering process and the intensity of treatment at the end-of-life of cancer patients is limited and remains unclear. Our objective was to examine the care-delivering processes in health care during the last months of life with real-life data of Swiss cancer patients. Patients and methods: The study population consisted of adult decedents in 2014 who were insured at Helsana Group. Data on the final cause of death were provided additionally by the Swiss Federal Statistical Office...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29587914/-surgical-treatment-of-refractory-chest-tumors-assisted-by-cardiopulmonary-bypass
#6
Rongying Zhu, Shanzhou Duan, Wentao Yang, Li Shi, Fuquan Zhang, Yongbing Chen
BACKGROUND: A retrospective review of the surgical treatment of refractory chest tumors involving the heart or large vessels with cardiopulmonary bypass (CPB). METHODS: To summarize 11 cases of chest tumor patients who had undergone cardiopulmonary bypass surgery from January 2008 to May 2017 in our hospital, and analyze the general condition, clinical characteristics, treatment methods, postoperative hospitalization time, complications and follow-up results of all patients...
April 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29555258/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin-fluorouracil-and-irinotecan-both-either-with-or-without-bevacizumab-as-second-line-therapy-for-metastatic-colorectal-cancer-axept-a-multicentre-open-label-randomised-non-inferiority-phase
#7
Rui-Hua Xu, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, Masato Nakamura, Joong Bae Ahn, Yan-Hong Deng, Takeshi Kato, Sang-Hee Cho, Yi Ba, Hiroshi Matsuoka, Keun-Wook Lee, Tao Zhang, Yasuhide Yamada, Junichi Sakamoto, Young Suk Park, Tae Won Kim
BACKGROUND: Studies of a modified XELIRI (mXELIRI; capecitabine plus irinotecan) regimen suggest promising efficacy and tolerability profiles in the first-line and second-line settings. Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or without bevacizumab in both regimens, as a second-line therapy for metastatic colorectal cancer. METHODS: We did a multicentre, open-label, randomised, non-inferiority, phase 3 trial...
March 16, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29545229/in-patients-with-advanced-ovarian-cancer-primary-suboptimal-surgery-has-better-survival-outcome-than-interval-suboptimal-surgery
#8
Alpaslan Kaban, Samet Topuz, Pınar Saip, Hamdullah Sözen, Yavuz Salihoğlu
OBJECTIVE: It is known that optimal or complete cytoreduction is the most important factor in patients with advanced ovarian cancer. The aim of this study was to examine the results of patients who did not undergo optimal cytoreduction and to examine subgroup analysis based on neoadjuvant chemotherapy. MATERIAL AND METHODS: Patients with advanced ovarian cancer and suboptimal surgery were retrospectively reviewed. RESULTS: A total of 99 patients with a median age of 59...
March 16, 2018: Journal of the Turkish German Gynecological Association
https://www.readbyqxmd.com/read/29536254/-end-of-life-therapy-for-patients-dying-with-cancer-a-retrospective-database-study
#9
Fabiola Fuchs, Martin Robausch
BACKGROUND: The topic of "medical oversupply at the end-of-life" is being discussed intensively internationally. The aim of this paper is to present the data of end-of-life care in one region in Austria (Lower Austria). METHODS: The data basis for the end-of-life indicators was the routine data (secondary data analysis) of the Lower Austrian District Health Insurance Fund (NÖGKK) from 2015. The basic population consisted of persons with inpatient hospitalization with a cancer diagnosis...
March 13, 2018: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29533771/autophagy-inhibition-mediates-apoptosis-sensitization-in-cancer-therapy-by-relieving-foxo3a-turnover
#10
Brent E Fitzwalter, Christina G Towers, Kelly D Sullivan, Zdenek Andrysik, Maria Hoh, Michael Ludwig, Jim O'Prey, Kevin M Ryan, Joaquin M Espinosa, Michael J Morgan, Andrew Thorburn
Macroautophagy (autophagy) is intimately linked with cell death and allows cells to evade apoptosis. This has prompted clinical trials to combine autophagy inhibitors with other drugs with the aim of increasing the likelihood of cancer cells dying. However, the molecular basis for such effects is unknown. Here, we describe a transcriptional mechanism that connects autophagy to apoptosis. The autophagy-regulating transcription factor, FOXO3a, is itself turned over by basal autophagy creating a potential feedback loop...
March 12, 2018: Developmental Cell
https://www.readbyqxmd.com/read/29531840/updated-survival-outcomes-of-nej005-tcog0902-a-randomised-phase-ii-study-of-concurrent-versus-sequential-alternating-gefitinib-and-chemotherapy-in-previously-untreated-non-small-cell-lung-cancer-with-sensitive-egfr-mutations
#11
Satoshi Oizumi, Shunichi Sugawara, Koichi Minato, Toshiyuki Harada, Akira Inoue, Yuka Fujita, Makoto Maemondo, Satoshi Watanabe, Kazuhiko Ito, Akihiko Gemma, Yoshiki Demura, Shinichi Fukumoto, Hiroshi Isobe, Ichiro Kinoshita, Satoshi Morita, Kunihiko Kobayashi, Koichi Hagiwara, Keisuke Aiba, Toshihiro Nukiwa
Background: The North-East Japan Study Group (NEJ) 005/Tokyo Cooperative Oncology Group (TCOG) 0902 study has reported that first-line concurrent and sequential alternating combination therapies of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (gefitinib) plus platinum-based doublet chemotherapy (carboplatin/pemetrexed) offer promising efficacy with predictable toxicities for patients with EGFR -mutant non-small cell lung cancer. However, overall survival (OS) data were insufficient in the primary report because of the lack of death events...
2018: ESMO Open
https://www.readbyqxmd.com/read/29531838/chemotherapy-in-cancer-patients-undergoing-haemodialysis-a-nationwide-study-in-japan
#12
Taro Funakoshi, Takahiro Horimatsu, Michio Nakamura, Koichi Shiroshita, Koichi Suyama, Masashi Mukoyama, Takuro Mizukami, Tsutomu Sakurada, Eishi Baba, Kazuhiko Tsuruya, Akira Nozaki, Kensei Yahata, Yukinori Ozaki, Yoshifumi Ubara, Hisateru Yasui, Akihiro Yoshimoto, Shingo Fukuma, Naoya Kondo, Takeshi Matsubara, Kazuo Matsubara, Shunichi Fukuhara, Motoko Yanagita, Manabu Muto
Background: Cancer is a major cause of death in patients undergoing haemodialysis. However, information about the actual clinical practice of chemotherapy for patients with cancer undergoing haemodialysis is lacking. We conducted a nationwide survey using questionnaires on the clinical practice of chemotherapy for such patients. Patients and methods: The nationwide survey included patients undergoing haemodialysis who were subsequently diagnosed with cancer in 20 hospitals in Japan from January 2010 to December 2012...
2018: ESMO Open
https://www.readbyqxmd.com/read/29497791/nonmetastatic-pancreatic-cancer-improved-survival-with-chemoradiotherapy-40-gy-after-systemic-treatment
#13
Sebastian Bachmayer, Gerd Fastner, Andrea Vaszi, Wolfgang Iglseder, Peter Kopp, Josef Holzinger, Adam Dinnewitzer, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Klaus Emmanuel, Richard Greil, Felix Sedlmayer, Franz Zehentmayr
PURPOSE: The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy. PATIENTS AND METHODS: Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment...
March 1, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29480751/cancer-patients-dying-in-the-intensive-care-units-and-access-to-palliative-care
#14
Mathilde Ledoux, Colombe Tricou, Maxime Roux, Soazic Dreano-Hartz, Murielle Ruer, Marilène Filbet
BACKGROUND: In France, cancer has become the leading cause of death. Intensive care units (ICU) focus on survival, which may not be an appropriate setting to provide palliative care (PC) as needed by cancer patients and families. OBJECTIVE: To describe the cancer patients who died in the ICU in 2010 in a French academic medical center. DESIGN: Retrospective study Measurements: We reviewed medical records of all cancer patients who died in the ICU in 2010...
February 26, 2018: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/29464354/parp-inhibitors-in-platinum-sensitive-high-grade-serous-ovarian-cancer
#15
REVIEW
Robert D Morgan, Andrew R Clamp, D Gareth R Evans, Richard J Edmondson, Gordon C Jayson
PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death...
February 20, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29450452/effect-of-neoadjuvant-chemotherapy-plus-regional-hyperthermia-on-long-term-outcomes-among-patients-with-localized-high-risk-soft-tissue-sarcoma-the-eortc-62961-esho-95-randomized-clinical-trial
#16
Rolf D Issels, Lars H Lindner, Jaap Verweij, Rüdiger Wessalowski, Peter Reichardt, Peter Wust, Pirus Ghadjar, Peter Hohenberger, Martin Angele, Christoph Salat, Zeljko Vujaskovic, Soeren Daugaard, Olav Mella, Ulrich Mansmann, Hans Roland Dürr, Thomas Knösel, Sultan Abdel-Rahman, Michael Schmidt, Wolfgang Hiddemann, Karl-Walter Jauch, Claus Belka, Alessandro Gronchi
Importance: Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes. Objective: To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival. Design, Setting, and Participants: Open-label, phase 3 randomized clinical trial to evaluate the efficacy and toxic effects of neoadjuvant chemotherapy plus regional hyperthermia...
February 15, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29434048/hospital-end-of-life-care-in-haematological-malignancies
#17
Yvan Beaussant, Etienne Daguindau, Adrien Chauchet, Philippe Rochigneux, Christophe Tournigand, Régis Aubry, Lucas Morin
OBJECTIVE: To investigate patterns of care during the last months of life of hospitalised patients who died from different haematological malignancies. METHODS: Nationwide register-based study, including all hospitalised adults ≥20 years who died from haematological malignancies in France in 2010-2013. Outcomes included use of invasive cancer treatments and referral to palliative care. Percentages are adjusted for sex and age using direct standardisation. RESULTS: Of 46 629 inpatients who died with haematological malignancies, 24...
February 6, 2018: BMJ Supportive & Palliative Care
https://www.readbyqxmd.com/read/29433963/pertuzumab-and-trastuzumab-with-or-without-metronomic-chemotherapy-for-older-patients-with-her2-positive-metastatic-breast-cancer-eortc-75111-10114-an-open-label-randomised-phase-2-trial-from-the-elderly-task-force-breast-cancer-group
#18
Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altintas, Nathan Touati, Fatima Cardoso, Etienne Brain
BACKGROUND: Despite the high incidence of metastatic breast cancer and its related mortality in the elderly population, our knowledge about optimal treatment for older patients with cancer is far from adequate. We aimed to evaluate the efficacy of dual anti-HER2 treatment with or without metronomic chemotherapy in older patients with HER2-positive metastatic breast cancer. METHODS: We did a multicentre, open-label, randomised, phase 2 trial in 30 centres from eight countries in Europe, in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease, who were 70 years or older, or 60 years or older with confirmed functional restrictions defined by protocol, and had a life expectancy of more than 12 weeks and a performance status according to WHO scale of 0-3...
February 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29417291/management-and-survival-analysis-of-elderly-patients-with-a-cancer-in-the-digestive-system-who-refused-to-receive-anticancer-treatments
#19
Jun Wan, Shiping Xu, Yinqiao Wu, Benyan Wu, Dezhong Joshua Liao, Ningzhi Xu, Gangshi Wang
Treatment and management of cancers in elderly patients require some special considerations. A better understanding of how cancers progress in those elderly patients who have not received any anticancer treatments could better help us in treating these patients and in making end-of-life decisions. Over the past years, we had encountered 57 elderly patients, aged 75 to 94 years (87.6 on average), with a cancer in the digestive system, who refused to accept anticancer treatment but who did receive the best available supportive and palliative care...
February 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29394789/-a-case-of-gemcitabine-and-nab-paclitaxel-therapy-for-multiple-metastatic-pancreatic-cancer
#20
Yusuke Takashima, Jun Shibamoto, Yukino Kawamura, Maiko Nishida, Hidekazu Hiramoto, Fumiaki Ochi, Masahiro Tsujiura, Susumu Nakashima, Junshin Fujiyama, Mamoru Masuyama
Pancreatic cancer is one of the leading causes of cancer-related death in Japan. Nab-paclitaxel(nab-PTX)and gemcitabine( GEM)combination chemotherapysignificantlyimproved overall survival in a phase III trial(MPACT). This combination chemotherapyhas become one of the first-line treatments for patients with metastatic pancreatic cancer since December 2014. We report a case of a patient who underwent this chemotherapyfor recurrence of pancreatic head cancer. A 64-yearold man, who underwent curative resection of pancreatic cancer 2 years ago, relapsed with multiple lung metastases and a para-aortic nodal metastasis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
67076
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"